OSAM
ACRS icon

O'Shaughnessy Asset Management’s Aclaris Therapeutics ACRS Stock Holding History

O'Shaughnessy Asset Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-288
Closed -$5K – 1266
2021
Q3 		$5K Sell
288
-35
-11% -$561 ﹤0.01% 2313
2021
Q2 		$6K Sell
323
-1,391
-81% -$31.6K ﹤0.01% 2095
2021
Q1 		$43K Buy
1,714
+38
+2% +$743 ﹤0.01% 1436
2020
Q4 		$11K Buy
1,676
+324
+24% +$1.37K ﹤0.01% 1532
2020
Q3 		$3K Hold
1,352
– – ﹤0.01% 1547
2020
Q2 		$2K Buy
+1,352
New +$1.81K ﹤0.01% 1473
2020
Q1 		– Sell
-5,826
Closed -$11K – 1276
2019
Q4 		$11K Buy
+5,826
New +$9.65K ﹤0.01% 1270

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

O'Shaughnessy Asset Management's ACRS Position: Q4 2021 in Review

O'Shaughnessy Asset Management sold out of Aclaris Therapeutics (ACRS) in Q4 2021, closing a stake of 288 shares — an estimated $5K sold.

O'Shaughnessy Asset Management first reported a position in ACRS in Q4 2019 and held it in 7 quarters. The position peaked at $43K in Q1 2021. 133 funds tracked by Wall St. Rank hold ACRS as of Q4 2021.

  • O'Shaughnessy Asset Management reported no remaining Aclaris Therapeutics position as of Q4 2021 after selling out during the quarter.
  • O'Shaughnessy Asset Management sold 288 Aclaris Therapeutics shares in Q4 2021, an estimated $5K.
  • O'Shaughnessy Asset Management first reported a position in Aclaris Therapeutics in Q4 2019 and held it in 7 quarters.
  • O'Shaughnessy Asset Management's Aclaris Therapeutics position peaked at $43K in Q1 2021.
  • 133 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2021.

Based on O'Shaughnessy Asset Management's 13F filing for Q4 2021, filed 11 Feb 2022.